This is a prospective randomized controlled trial that aimed to compare the short-term clinical outcomes, functional outcomes, costs, and recurrence rates between endoscopic submucosal dissection (ESD) and transanal minimally invasive surgery (TAMIS) for early rectal neoplasms.
Background: Transanal minimally invasive surgery (TAMIS) is an effective surgical alternative to transanal excision for treating early rectal neoplasms not amenable to en bloc resection by conventional colonoscopic techniques. Endoscopic submucosal dissection (ESD) is a revolutionary endoscopic procedure that enables en bloc resection of large rectal neoplasms with low morbidity. To date, no randomized controlled trial can be found in the literature comparing the two modalities. Objectives: To compare the short-term clinical outcomes, functional outcomes, costs, and recurrence rates between ESD and TAMIS for early rectal neoplasms. Design: Prospective randomized controlled trial. Subjects: One hundred and fourteen consecutive patients diagnosed with early rectal neoplasms (\>/=2 cm in size and without evidence of deep submucosal invasion) that are not amenable to en bloc resection by conventional colonoscopic techniques will be recruited. Interventions: Patients will be randomly allocated to receive either ESD or TAMIS. Outcome measures: Primary outcome: 30-day morbidity/mortality defined by the Clavien-Dindo classification. Secondary outcomes: hospital stay, functional outcomes and quality of life, overall costs, R0 resection rate, and recurrence rate. Conclusions: Results of the present study can provide evidence-based clarification of the efficacy and safety of ESD in treating early rectal neoplasms. The Investigators hypothesize that ESD is associated with lower morbidity, shorter hospital stay, and similar R0 resection rate when compared with TAMIS. A faster recovery and earlier discharge after ESD may reduce financial burden to the hospital/healthcare system. The results of this proposed project may have a significant impact on the future treatment strategy for early rectal neoplasms.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
114
Prince of Wales Hospital
Hong Kong, Hong Kong
RECRUITINGShort-term morbidity
Short-term morbidity/mortality within 30 days after the procedure (including intraprocedural morbidity/mortality), defined by the Clavien-Dindo classification of surgical complications
Time frame: Up to 1 month
En bloc resection rate
Resection with a single piece
Time frame: Up to 1 month
R0 resection rate
Complete resection of the neoplasm with clear lateral and deep margins at histology
Time frame: Up to 1 month
Time to resume normal diet
Time frame: Up to 1 month
Time to walk independently
Time frame: Up to 1 month
Length of hospital stay
Time frame: Up to 1 month
Anal continence
Measured by the Wexner's score
Time frame: Up to 1 year
Fecal incontinence quality of life (FIQL)
Measured by the FIQL questionnaire
Time frame: Up to 1 year
Quality of life measured by the Short Form-36 (SF-36) Health Survey questionnaire
SF-36 Health Survey is a 36-item, patient-reported survey of patient health. It consists of eight scaled scores, which are the weighted sums of the questions in their section. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to 1 year
Direct medical costs
Time frame: Up to 1 year
Local recurrence
Time frame: Up to 3 years